ReviewOncoimmunology
Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.
Review in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 147 citations in OpenAlex.
- Mortality of COVID-19 in patients with hematological malignancies versus solid tumors: a systematic literature review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Deep visual multi-omics profiling links morphology and molecular programs in clear cell renal cell carcinoma.EMBO molecular medicine · 2026Article
- Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy.Cancer immunology research · 2026Article
- PARP7 and aryl hydrocarbon receptor differentially regulate mammary cancer cell proliferation and STING-induced type I interferon signalling.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Blockade of CC chemokine receptor 2 suppresses pancreatic cancer progression through the interaction with macrophages in the tumor microenvironment.Scientific reports · 2025Article
- VAX014 Activates Tumor-Intrinsic STING and RIG-I to Promote the Development of Antitumor Immunity.Molecular cancer therapeutics · 2025Article
- FAM210B activates STAT1/IRF9/IFIT3 axis by upregulating IFN-α/β expression to impede the progression of lung adenocarcinoma.Cell death & disease · 2025Article
- Single-cell RNA sequencing and spatial transcriptomics of esophageal squamous cell carcinoma with lymph node metastases.Experimental & molecular medicine · 2025Article
- Phosphatidylserine (PS)-targeting chimeric Interferon (IFN) fusion proteins for anti-tumor applications.bioRxiv : the preprint server for biology · 2025Article
- Innate immune-inflammatory signaling milieu in myeloid leukemia and aging-associated clonal hematopoiesis pathologies.Frontiers in immunology · 2025Review
- Identification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer.Journal of cancer research and clinical oncology · 2024Article
- A STAT3-STING-IFN axis controls the metastatic spread of small cell lung cancer.Nature immunology · 2024Article
- LAMTOR1 ablation impedes cGAS degradation caused by chemotherapy and promotes antitumor immunity.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Type I interferon signaling regulates myeloid and T cell crosstalk in the glioblastoma tumor microenvironment.iScience · 2024Article
- Impact of Genomic Mutation on Melanoma Immune Microenvironment and IFN-1 Pathway-Driven Therapeutic Responses.Cancers · 2024Article
- Type I Interferon Activates PD-1 Expression through Activation of the STAT1-IRF2 Pathway in Myeloid Cells.Cells · 2024Article
- Secretion of functional interferon by the type 3 secretion system of enteropathogenic Escherichia coli.Microbial cell factories · 2024Article
- Review
- Loss ofFrontiers in immunology · 2024Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
If there is a great new hope in the treatment of cancer, the immune system is it. Innate and adaptive immunity either promote or attenuate tumorigenesis and so can have opposing effects on the therapeutic outcome. Originally described as potent antivirals, Type-I interferons (IFNs) were quickly recognized as central coordinators of tumor-immune system interactions. Type-I-IFNs are produced by, and act on, both tumor and immune cells being either host-protecting or tumor-promoting. Here, we discuss Type-I-IFNs in infectious and cancer diseases highlighting their dichotomous role and raising the importance to deeply understand the underlying mechanisms so to reshape the way we can exploit Type-I-IFNs therapeutically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.